Standardised second-line treatment of multidrug-resistant tuberculosis during pregnancy

被引：24
作者：
Tabarsi, P. [2 ]
Moradi, A. [1 ,2 ]
Baghaei, P. [2 ]
Marjani, M. [2 ]
Shamaei, M. [2 ]
Mansouri, N. [2 ]
Chitsaz, E. [2 ]
Farnia, P. [2 ,3 ]
Mansouri, D. [2 ]
Masjedi, M. [2 ]
Velayati, A. [2 ]
机构：
[1] Shahid Beheshti Univ Med Sci, Masih Daneshvari Hosp, Natl Res Inst TB & Lung Dis, Virol Res Ctr, Tehran, Iran
[2] Shahid Beheshti Univ Med Sci, Masih Daneshvari Hosp, Natl Res Inst TB & Lung Dis, Mycobacteriol Res Ctr, Tehran, Iran
[3] Shahid Beheshti Univ Med Sci, Masih Daneshvari Hosp, Natl Res Inst TB & Lung Dis, Chron Resp Dis Res Ctr, Tehran, Iran
来源：
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE | 2011年 / 15卷 / 04期
关键词：
MDR-TB; standardised second-line anti-tuberculosis medications; pregnancy; MDR-TB; IRAN;
D O I：
10.5588/ijtld.10.0140
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
We describe the efficacy and outcome of standardised second-line anti-tuberculosis (TB) medications during pregnancy. Treatment outcomes of five pregnant women with documented multidrug-resistant TB (MDR-TB) referred to the National Research Institute of Tuberculosis and Lung Diseases from 2003 to 2009 were analysed in two categories, maternal and neonatal. Patients became pregnant during treatment for MDR-TB without any changes in their anti-tuberculosis regimen. None of them had any adverse effects during pregnancy and delivery. No adverse effects were observed in mothers or neonates. The treatment of MDR-TB during pregnancy with a standardised second-line regimen in this study population was safe, with an acceptable rate of treatment success.
引用
收藏
页码：547 / 550
页数：4
相关论文
共 14 条
  • [1] The safety of quinolones-A meta-analysis of pregnancy outcomes
    Bar-Oz, Benjamin
    Moretti, Myla E.
    Boskovic, Radinka
    O'Brien, Lisa
    Koren, Gideon
    [J]. EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2009, 143 (02) : 75 - 78
  • [2] Treatment of multidrug-resistant tuberculosis during pregnancy: Long-term follow-up of 6 children with intrauterine exposure to second-line agents
    Drobac, PC
    del Castillo, H
    Sweetland, A
    Anca, G
    Joseph, JK
    Furin, J
    Shin, S
    [J]. CLINICAL INFECTIOUS DISEASES, 2005, 40 (11) : 1689 - 1692
  • [3] Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally
    Dye, C
    Watt, CJ
    Bleed, DM
    Hosseini, SM
    Raviglione, MC
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 293 (22): : 2767 - 2775
  • [4] Khan M, 2007, INT J TUBERC LUNG D, V11, P706
  • [5] Klaus-Dieter K, 2003, CHEST, V123, P953
  • [6] Laserson KF, 2005, INT J TUBERC LUNG D, V9, P640
  • [7] Masjedi MR, 2008, INT J TUBERC LUNG D, V12, P750
  • [8] Treatment of multiple drug-resistant tuberculosis (MDR-TB) in Iran
    Mirsaeidi, SM
    Tabarsi, P
    Khoshnood, K
    Pooramiri, MV
    Rowhani-Rahbar, A
    Mansoori, SD
    Masjedi, H
    Zahirifard, S
    Mohammadi, F
    Farnia, P
    Masjedi, MR
    Velayati, AA
    [J]. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2005, 9 (06) : 317 - 322
  • [9] Management of four pregnant women with multidrug-resistant tuberculosis
    Nitta, AT
    Milligan, D
    [J]. CLINICAL INFECTIOUS DISEASES, 1999, 28 (06) : 1298 - 1304
  • [10] Global surveillance for antituberculosis-drug resistance, 1994-1997
    Pablos-Méndez, A
    Raviglione, MC
    Laszlo, A
    Binkin, N
    Rieder, HL
    Bustreo, F
    Cohn, DL
    Lambregts-van Weezenbeek, CSB
    Kim, SJ
    Chaulet, P
    Nunn, P
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (23) : 1641 - 1649
12